Identification and characterization of CML stem cell during TKI treatment
Project/Area Number |
25860796
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Hematology
|
Research Institution | Kinki University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 慢性骨髄性白血病 / 白血病幹細胞 / 微小残存病変 / miRNA |
Outline of Final Research Achievements |
TKIs have dramatically improved clinical outcomes of the patients with CML-CP. However, even if these patients maintained deep molecular responses, discontinuation of TKI results in early relapse in most cases. Therefore, new therapeutic strategies to eradicate CML stem cells (LSCs) are required to cure CML. We previously identified CD120a, CD225, and CD284 as novel surface molecules on LSCs. Our examination of clinical samples revealed that the detection of these molecules on CD34+CD38- cells might be helpful to evaluate therapeutic effects and to monitor condition changes in CML patients. Also, because TNFα-CD120a-NF-κB signaling promoted LSC proliferation, targeting these molecules may represent an attractive therapeutic approach to eradicate CML stem cells. On the other hands, expression analysis of miRNA which control the level of Abl indicated that epigenetic state of mir-203 promoter was diverse, thereby inducing various expression levels of Bcr/Abl in individual LSCs.
|
Report
(4 results)
Research Products
(23 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Analysis of conditioning regimen for ASCT with relapsed or refractory malignant lymphoma2014
Author(s)
Kentaro Serizawa,Yasuyoshi Morita,Takahide Taniguchi,Yasuyo Oyama,Masaya Kawauchi,Takahiro Kumode,Yoshitaka kanai,Chikara Hirase,Hirokazu Tanaka,Jyunichi Miyatake,Youichi Tatsumi,Takashi Ashisda,Itaru Matsumura
Organizer
第76回日本血液学会学術集会
Place of Presentation
大阪・大阪国際会議場
Year and Date
2014-10-31 – 2014-11-02
Related Report
-
-
-
[Presentation] Results of gemcitabine therapy for relapsed of refractory Non-Hodgkin's lymphoma in one institute.2013
Author(s)
Serizawa K, Morita Y, Taniguchi Y, Kawauchi M, Eguchi G, Emoto M, Kanai Y, Rai S, Hirase C, Tanaka H, Shimada T, Tatsumi Y, Ashida T, Matsumura I.
Organizer
第75回日本血液学会学術集会
Place of Presentation
ロイトン札幌・さっぽろ芸文館・札幌市教育文化会館
Related Report
-
[Presentation] Trib1 and Trib2 block myeloid differentiation by suppressing AKT phosphorylation.2013
Author(s)
Kanai Y, Shimada T, Taniguchi Y, Rai S, Hirase C, Morita Y, Tanaka H, Miyatake J, Tatsumi Y, Ashida T, Matsumura I.
Organizer
第75回日本血液学会学術集会
Place of Presentation
ロイトン札幌・さっぽろ芸文館・札幌市教育文化会館
Related Report
-
-
-
-
-